Cancer ScreeningSCREENNCT07755163
Screening Cancer Readiness Through Education and Empowerment for Newcomer Women
A study testing Screening Cancer Readiness through Education and Empowerment for Newcomer Women in people with Cancer Screening and Early Detection of Cancer, run by Erzincan Binali Yildirim Universitesi.
Trial summary
Purpose: This study was conducted to determine the effect of an online educational intervention on migrant women's knowledge and attitudes toward cancer screening. DesigN:This study was designed as a two-arm, parallel-group, randomized controlled trial with pre-test and post-test assessments. Read more about this study
- Who is it for?
- Ages 30 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Cancer Screening, Early Detection of Cancer, Migrants
- What is being tested?
- Screening Cancer Readiness through Education and Empowerment for Newcomer Women
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- 6 Aug 2026to 25 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Women aged 30-70 years. Able to read and write. Able to speak and understand Turkish. Have access to the internet at home or in the workplace. Own a smartphone or have access to a smartphone belonging to a family member that can be used by the participant.
- Have no hearing, visual, cognitive, or orthopedic impairments that would prevent participation in the study.
- -
- Exclusion Criteria:Presence of cognitive, visual, or orthopedic impairment that may interfere with participation in the study.
- Diagnosis of a psychiatric disorder.
- -
Who cannot join
None listed.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: The Effect of Online Education on Knowledge and Attitudes Toward Cancer Screening Among Migrant Women: A Randomized Controlled Trial
Purpose: This study was conducted to determine the effect of an online educational intervention on migrant women's knowledge and attitudes toward cancer screening.
DesigN:This study was designed as a two-arm, parallel-group, randomized controlled trial with pre-test and post-test assessments.
Method: The study population will consist of women registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM) affiliated with the Erzincan Provincial Health Directorate. The sample size was calculated based on a two-group (intervention and control) and two-measurement (pre-test and post-test) study design. Using repeated-measures ANOVA with a medium effect size (d = 0.25), a significance level of 5% (α = 0.05), and a statistical power of 80% (1 - β = 0.80), the required sample size was determined to be 34 participants per group (34 in the intervention group and 34 in the control group), resulting in a minimum total sample of 68 participants. To account for potential attrition, it was planned to recruit 80 participants (approximately 20% more than the minimum required sample size).
- Conditions
- Cancer Screening, Early Detection of Cancer, Migrants
- Being tested
- Screening Cancer Readiness through Education and Empowerment for Newcomer Women, Control group
- Keywords
- Migrant women, Cancer screening, Online education, Knowledge and attitudes
- Medical subject headings
- Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Screening Cancer Readiness through Education and Empowerment for Newcomer WomenOther
Women assigned to the intervention group will be contacted by telephone using the contact information registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM). For participants without a registered telephone number, home visits will be conducted using the addresses recorded in the KETEM database. Following completion of the baseline (pre-test) assessment, participants in the intervention group will receive an online cancer screening education program developed in accordance with the Turkish National Cancer Control Program of the General Directorate of Public Health, Ministry of Health of the Republic of Türkiye. The educational intervention will be delivered in three online sessions via WhatsApp video calls. During each session, participants will have the opportunity to ask questions, which will be answered by the researcher. Prior to each session, reminder text messages will be sent to participants' mobile phones to notify them of the date and time of the schede
Control groupOther
Women assigned to the control group who are registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM) will be contacted and invited to participate in the study. During the initial meeting, written informed consent will be obtained, after which the Personal Information Form and study questionnaires will be administered to collect baseline (pre-test) data. An appointment for the follow-up assessment will be scheduled approximately four weeks later. Five weeks after the baseline assessment, participants will be contacted by telephone to complete the post-test assessment. No educational intervention will be provided to the control group during the study period. After completion of the post-test assessment, participants in the control group will be offered the same cancer screening education program in accordance with the ethical principle of equity.
| Study group | Role | What they receive |
|---|---|---|
| SCREEN | Experimental | Not described Receives: Other: Screening Cancer Readiness through Education and Empowerment for Newcomer Women |
| control group | Active comparator | Not described Receives: Other: Control group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cancer Screening Knowledge Scale
The Cancer Screening Knowledge Scale is a 25-item questionnaire designed to assess participants' knowledge regarding cancer screening. Total scores range from 0 to 25, with higher scores indicating greater knowledge.
Measured: From baseline to 5 weeks after baseline
Cancer Screening Attitude Scale-Short Form
The Cancer Screening Attitude Scale-Short Form is a 15-item questionnaire used to assess participants' attitudes toward cancer screening. Total scores range from 15 to 75, with higher scores indicating more positive attitudes toward cancer screening.
Measured: From baseline to 5 weeks after baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2026
- Study start6 Aug 2026 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion25 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer ScreeningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Erzincan Binali Yildirim Universitesi
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ezgi DEMİRTÜRK SELÇUK, Erzincan Binali Yildirim Universitesi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07755163
- Sponsor's protocol ID
- 0413
- Acronym
- SCREEN
- Status last verified
- Aug 2026
- First submitted
- 5 Aug 2026
- Last updated
- 10 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Online Education on Knowledge and Attitudes Toward Cancer Screening Among Migrant Women: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07755163
- Acronym / sponsor ID
- SCREEN / 0413
- Conditions
- Cancer Screening, Early Detection of Cancer, Migrants
- Keywords
- Migrant women, Cancer screening, Online education, Knowledge and attitudes
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Erzincan Binali Yildirim UniversitesiUniversity, hospital or other
- Study start
- 6 Aug 2026 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 25 Jan 2027 (estimated)
- First posted
- 10 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Purpose: This study was conducted to determine the effect of an online educational intervention on migrant women's knowledge and attitudes toward cancer screening.
DesigN:This study was designed as a two-arm, parallel-group, randomized controlled trial with pre-test and post-test assessments.
Method: The study population will consist of women registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM) affiliated with the Erzincan Provincial Health Directorate. The sample size was calculated based on a two-group (intervention and control) and two-measurement (pre-test and post-test) study design. Using repeated-measures ANOVA with a medium effect size (d = 0.25), a significance level of 5% (α = 0.05), and a statistical power of 80% (1 - β = 0.80), the required sample size was determined to be 34 participants per group (34 in the intervention group and 34 in the control group), resulting in a minimum total sample of 68 participants. To account for potential attrition, it was planned to recruit 80 participants (approximately 20% more than the minimum required sample size).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SCREEN | Experimental | Other: Screening Cancer Readiness through Education and Empowerment for Newcomer Women |
| control group | Active comparator | Other: Control group |
Who may qualify
- Ages
- 30 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Women aged 30-70 years. Able to read and write. Able to speak and understand Turkish. Have access to the internet at home or in the workplace. Own a smartphone or have access to a smartphone belonging to a family member that can be used by the participant.
- Have no hearing, visual, cognitive, or orthopedic impairments that would prevent participation in the study.
- -
- Exclusion Criteria:Presence of cognitive, visual, or orthopedic impairment that may interfere with participation in the study.
- Diagnosis of a psychiatric disorder.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Screening Cancer Readiness through Education and Empowerment for Newcomer WomenWomen assigned to the intervention group will be contacted by telephone using the contact information registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM). For participants without a registered telephone number, home visits will be conducted using the addresses recorded in the KETEM database. Following completion of the baseline (pre-test) assessment, participants in the intervention group will receive an online cancer screening education program developed in accordance with the Turkish National Cancer Control Program of the General Directorate of Public Health, Ministry of Health of the Republic of Türkiye. The educational intervention will be delivered in three online sessions via WhatsApp video calls. During each session, participants will have the opportunity to ask questions, which will be answered by the researcher. Prior to each session, reminder text messages will be sent to participants' mobile phones to notify them of the date and time of the schede | Other | SCREEN |
| Control groupWomen assigned to the control group who are registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM) will be contacted and invited to participate in the study. During the initial meeting, written informed consent will be obtained, after which the Personal Information Form and study questionnaires will be administered to collect baseline (pre-test) data. An appointment for the follow-up assessment will be scheduled approximately four weeks later. Five weeks after the baseline assessment, participants will be contacted by telephone to complete the post-test assessment. No educational intervention will be provided to the control group during the study period. After completion of the post-test assessment, participants in the control group will be offered the same cancer screening education program in accordance with the ethical principle of equity. | Other | control group |
Primary outcome
Cancer Screening Knowledge Scale
Time frame: From baseline to 5 weeks after baseline
The Cancer Screening Knowledge Scale is a 25-item questionnaire designed to assess participants' knowledge regarding cancer screening. Total scores range from 0 to 25, with higher scores indicating greater knowledge.
Cancer Screening Attitude Scale-Short Form
Time frame: From baseline to 5 weeks after baseline
The Cancer Screening Attitude Scale-Short Form is a 15-item questionnaire used to assess participants' attitudes toward cancer screening. Total scores range from 15 to 75, with higher scores indicating more positive attitudes toward cancer screening.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer Screening
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Not yet recruitingObservational study
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
Pancreatic Cancer, Advanced or Metastatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Screening Cancer Readiness through Education and Empowerment for Newcomer Women in people with Cancer Screening and Early Detection of Cancer, run by Erzincan Binali Yildirim Universitesi.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ezgi Demirtürk Selçuk, PhD (+905448502161, demirturkezgi@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cancer Screening Knowledge Scale (time frame: From baseline to 5 weeks after baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.